<HashMap><database>biostudies-literature</database><scores/><additional><omics_type>Unknown</omics_type><volume>13(1)</volume><submitter>Kinoshita F</submitter><pubmed_abstract>There are great expectations for artificial intelligence (AI) in medicine. We aimed to develop an AI prognostic model for surgically resected non-small cell lung cancer (NSCLC). This study enrolled 1049 patients with pathological stage I-IIIA surgically resected NSCLC at Kyushu University. We set 17 clinicopathological factors and 30 preoperative and 22 postoperative blood test results as explanatory variables. Disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS) were set as objective variables. The eXtreme Gradient Boosting (XGBoost) was used as the machine learning algorithm. The median age was 69 (23-89) years, and 605 patients (57.7%) were male. The numbers of patients with pathological stage IA, IB, IIA, IIB, and IIIA were 553 (52.7%), 223 (21.4%), 100 (9.5%), 55 (5.3%), and 118 (11.2%), respectively. The 5-year DFS, OS, and CSS rates were 71.0%, 82.8%, and 88.7%, respectively. Our AI prognostic model showed that the areas under the curve of the receiver operating characteristic curves of DFS, OS, and CSS at 5 years were 0.890, 0.926, and 0.960, respectively. The AI prognostic model using XGBoost showed good prediction accuracy and provided accurate predictive probability of postoperative prognosis of NSCLC.</pubmed_abstract><journal>Scientific reports</journal><pagination>15683</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC10514331</full_dataset_link><repository>biostudies-literature</repository><pubmed_title>Development of artificial intelligence prognostic model for surgically resected non-small cell lung cancer.</pubmed_title><pmcid>PMC10514331</pmcid><pubmed_authors>Nakashima N</pubmed_authors><pubmed_authors>Mori M</pubmed_authors><pubmed_authors>Wakasu S</pubmed_authors><pubmed_authors>Kinoshita F</pubmed_authors><pubmed_authors>Yamashita T</pubmed_authors><pubmed_authors>Ono Y</pubmed_authors><pubmed_authors>Tagawa T</pubmed_authors><pubmed_authors>Matsumoto K</pubmed_authors><pubmed_authors>Oku Y</pubmed_authors><pubmed_authors>Takenaka T</pubmed_authors><pubmed_authors>Haratake N</pubmed_authors></additional><is_claimable>false</is_claimable><name>Development of artificial intelligence prognostic model for surgically resected non-small cell lung cancer.</name><description>There are great expectations for artificial intelligence (AI) in medicine. We aimed to develop an AI prognostic model for surgically resected non-small cell lung cancer (NSCLC). This study enrolled 1049 patients with pathological stage I-IIIA surgically resected NSCLC at Kyushu University. We set 17 clinicopathological factors and 30 preoperative and 22 postoperative blood test results as explanatory variables. Disease-free survival (DFS), overall survival (OS), and cancer-specific survival (CSS) were set as objective variables. The eXtreme Gradient Boosting (XGBoost) was used as the machine learning algorithm. The median age was 69 (23-89) years, and 605 patients (57.7%) were male. The numbers of patients with pathological stage IA, IB, IIA, IIB, and IIIA were 553 (52.7%), 223 (21.4%), 100 (9.5%), 55 (5.3%), and 118 (11.2%), respectively. The 5-year DFS, OS, and CSS rates were 71.0%, 82.8%, and 88.7%, respectively. Our AI prognostic model showed that the areas under the curve of the receiver operating characteristic curves of DFS, OS, and CSS at 5 years were 0.890, 0.926, and 0.960, respectively. The AI prognostic model using XGBoost showed good prediction accuracy and provided accurate predictive probability of postoperative prognosis of NSCLC.</description><dates><release>2023-01-01T00:00:00Z</release><publication>2023 Sep</publication><modification>2025-04-04T21:02:33.885Z</modification><creation>2025-04-04T21:02:33.885Z</creation></dates><accession>S-EPMC10514331</accession><cross_references><pubmed>37735585</pubmed><doi>10.1038/s41598-023-42964-8</doi></cross_references></HashMap>